Health2Sync
Diabetes management app with 1.6M users, just IPO'd on Taiwan's TPEx exchange.
On the record
Checkpoint: First post-IPO TPEx quarterly filings expected to confirm or refute revenue and clinic retention
The call
Health2Sync shipped a real product and got to a real IPO, but the same pharma partners funding it could build around it, and AI can already do part of what it sells.
Health2Sync is a smartphone app and clinic platform that uses artificial intelligence to help people with diabetes adjust their insulin doses, serving 1.6 million users across over 800 clinics in Asia. The company is hard to replace because it has existing relationships with major drug makers like Novo Nordisk and Sanofi, plus it connects to blood sugar monitors and insulin pumps. However, it is also easy to replace: the drug companies themselves can build their own apps and bypass Health2Sync entirely, and recent research published in medical journals proves that AI can recommend insulin doses just as well as doctors do, meaning the skill Health2Sync sells is becoming a commodity. The one thing that could change everything is whether Novo Nordisk or Sanofi actually launch their own competing apps in the next 12 to 18 months.
Why
01
AI pressure: AI-driven insulin titration tools (JAMA Network Open 2025 conversational AI trial, iNCDSS). Peer-reviewed trials show AI matching or beating doctors at insulin dosing, the exact job Health2Sync's app is built around. Could AI do the core job? Yes, likely.
02
Bigger players: Novo Nordisk, Sanofi, Abbott. Health2Sync's own pharma and device partners have the data and reach to build direct-to-patient AI apps that skip the middleman. Could a giant copy it? Yes, easily.
03
What protects it. 800+ clinic contracts and 80+ device integrations across Taiwan, Japan, Korea create switching friction pharma giants haven't bothered to overcome yet.
What would change this call
Novo Nordisk or Sanofi launches a direct-to-consumer AI diabetes app in Taiwan, Japan, or Korea within 12 to 18 months. Would show pharma partners are disintermediating Health2Sync's core platform role.
Health2Sync's first two TPEx quarterly filings (Q1 to Q2 2026) report revenue and clinic retention figures. Would confirm or refute the unverified $23.1M revenue estimate and subscription stickiness.
Glooko, WellDoc, or Roche mySugr announce expansion into Taiwan, Japan, or Korea clinic markets. Would show direct rivals moving into Health2Sync's regional stronghold.
Health2Sync's first two TPEx quarterly filings (Q1 to Q2 2026) report revenue and clinic retention figures. Would confirm or refute the unverified $23.1M revenue estimate and subscription stickiness.
Glooko, WellDoc, or Roche mySugr announce expansion into Taiwan, Japan, or Korea clinic markets. Would show direct rivals moving into Health2Sync's regional stronghold.
Key numbers
- 1.6M registered users, 800+ clinics
- IPO'd Nov 2025 on TPEx, ticker 7851, ~US$50M market cap
- $20M Series C in March 2025 aimed at IPO
Named risks
- Pharma partners (Novo Nordisk, Sanofi, Abbott) could build direct AI ecosystems bypassing Health2Sync's platform.
- Peer-reviewed 2025 AI insulin titration trials show noninferiority to physicians, threatening core coaching workflow.
- Aggregator-estimated $23.1M revenue is unverified by primary financial filings post-IPO.
- Small headcount (roughly 50-110 employees) versus larger-funded rivals like Glooko and WellDoc.
- Regional language and certification lock-in slows but does not structurally bar larger competitors from entering Asia.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Novo Nordisk / Sanofi | contesting | Both partner and potential disintermediator; JAMA RCT (May 2025) proves AI titration viable for direct-to-consumer use |
| Glooko | contesting | Larger US-based platform with comparable device integrations, acquired DIABNEXT in 2024 |
| WellDoc | contesting | AI-driven chronic disease platform with roughly $65M raised, overlapping device integration model |
| mySugr (Roche) | gaining on | Backed by Roche's global device and pharma distribution, competing diabetes app |
| Teladoc Health (Livongo) | gaining on | Larger-scale chronic-care coaching platform following Livongo acquisition |
Questions people ask
- Is Health2Sync profitable in 2026?
- No confirmed profitability data exists. Health2Sync listed on Taiwan's TPEx under ticker 7851 in November 2025, and its first post-IPO quarterly filings, due around 2026, are expected to verify or refute an aggregator-estimated $23.1M annual revenue figure that is currently unconfirmed.
- Could AI replace Health2Sync's core insulin-coaching feature?
- A JAMA Network Open RCT published May 6, 2025 found an AI tool (iNCDSS) noninferior to senior endocrinologists on insulin titration, with 99% of AI dose recommendations adopted by physicians, directly threatening the coaching workflow Health2Sync's app is built around.
- Who owns Health2Sync now?
- Health2Sync was VC-backed (WI Harper Group, Cherubic Ventures, Taiwania Capital, Wistron, Pegatron among investors) before completing an IPO on Taiwan's TPEx exchange under ticker 7851 on November 18, 2025, as corporate entity H2, Inc.
- Is Health2Sync a safe company to join in 2026?
- Health2Sync has a real shipped product with 1.6 million registered users and 800+ contracted hospitals/clinics as of mid-2026, per its own AWS case study, and just completed a Taiwan IPO in November 2025, but headcount remains small (roughly 50 to 110 by industry estimates) and its financials are not yet independently verified.
- Who is Health2Sync's biggest competitor?
- Health2Sync competes most directly with Glooko, WellDoc, and Roche-owned mySugr, all of which offer comparable device integrations and clinical partnerships; larger incumbents like Teladoc (post-Livongo acquisition) also compete in chronic-disease coaching at greater scale.
- Has Health2Sync had layoffs?
- No dated news of layoffs was found as of mid-2026. The company instead expanded in this period, closing a $20M Series C round in March 2025 explicitly to fund its Taiwan IPO and first digital therapeutics product, and extending device integrations into South Korea in July 2025.
Timeline
- 2025-11-18Health2Sync completes IPO on Taiwan's TPEx under ticker 7851 as H2, Inc.
- 2025-07Expanded Mallya Cap smart insulin pen integration (BIOCORP/Novo Nordisk) into South Korea
- 2025-05-06JAMA Network Open RCT shows AI tool noninferior to endocrinologists on insulin titration
- 2025-03-10Closed $20M Series C round explicitly earmarked for Taiwan IPO and digital therapeutics product
- 2025-03Launched Lab Report Scanning feature for lab result tracking
- 2025-02Named to Forbes Asia's 100 to Watch 2025 list
- 2024-07Signed MOU with Merdury Biopharmaceutical (Taiwan-listed pharma)
- 2022-07-15Signed AstraZeneca Taiwan MOU for chronic kidney disease management
- 2022-01-18Signed Sanofi Japan MOU for digital therapeutics and insulin management
- 2017-12-06Raised $6M Series B round
Revision history
30 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- H2, Inc. (7851) Company Information
- Health2Sync drives worldwide expansion while reducing deployment cycles by 40% (2026-07-15)
- Health2Sync
- Health2Sync - Overview, News & Similar companies (2026-07-06)
- Digital Health Startup... (2016-08-30)
- Health2Sync raises $6M... (2017-12-06)
- Health2Sync eyes Taiwan IPO with $20M Series C fund (2025-03-10)
- Valuation, Funding Rounds & Stock Price (2026-07-05)
- Products, Competitors, Financials... (2026-05-31)
- Health2Sync Expands Product Offering... (2022-01-18)
- AI Tool Helped Endocrinologists Titrate Insulin... (2025-05-06)
- Use of Voice-Based Conversational AI for Basal Insulin Prescription Management...